Clinical trials: Patients With Tumor
Advanced Solid Tumor
Study to Assess AFM24 in Advanced Solid Cancers
AFM24-101 is a first in human Phase 1/2a open-label, non-randomized, multi-center, multiple ascending dose escalation/expansion study evaluating AFM24 as monotherapy in patients with advanced solid malignancies whose disease has…
- Trial name
- NCT04259450
- Testing
- 14 mg AFM24, 40 mg AFM24, 80 mg AFM24
- Where
- 13 sites in United States, Germany and 3 more
- Volunteers
- 85 people
- Sponsor
- Affimed GmbH
Advanced Solid Tumor
Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies
To estimate the maximum tolerated dose (MTD) or recommended dose for phase II (RP2D) of CLR457 and to investigate the anti-tumor activity of CLR457
- Trial name
- NCT02189174
- Testing
- CLR457
- Where
- 7 sites in United States, Canada and 3 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Lung Neoplasms, Respiratory Tract Neoplasms
Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC
This Expanded Access Program will provide access of taletrectinib therapy to patients with locally advanced or metastatic ROS1-positive NSCLC who are not an appropriate candidate for an approved therapy, for any ongoing…
- Conditions
- Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site
- Trial name
- Tale EAP (NCT06841874)
- Testing
- Taletrectinib
- Sponsor
- Nuvation Bio Inc.
Lung Malignancy
Validating Artificial Intelligence Effectiveness Defined Lung Nodule Malignancy Score in Patients With Pulmonary Nodule.
Artificial intelligence (AI) based algorithms have demonstrated increased accuracy in predicting the risk of Lung Cancer among patients with an incidental pulmonary nodule (IPN) on chest radiographs.
- Trial name
- CREATE (NCT05817110)
- Testing
- Participant Cohort
- Where
- 22 sites in Egypt, India and 3 more
- Volunteers
- 712 people
- Sponsor
- AstraZeneca
Hodgkin's Lymphoma
Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
MGCD0103 is an experimental drug that belongs to a class of drugs known as the histone deacetylase inhibitors, which may restore normal control in cancer cells by affecting the genes and proteins that are being made.
- Trial name
- NCT00358982
- Testing
- MGCD0103
- Where
- 5 sites in United States, Canada
- Volunteers
- 51 people
- Sponsor
- Mirati Therapeutics Inc.
Hematologic Malignancy
Impact of Palliative Transfusions on Quality of Life in Patients With Blood Cancers on Hospice
The purpose of this pilot research study is to evaluate the effectiveness of blood and platelet transfusions in improving symptoms and quality of life of patients enrolled in hospice.
- Trial name
- PalliaQOL (NCT04454723)
- Testing
- Blood and/or platelet transfusion, Complete blood count (CBC) collection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Oklahoma
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
This phase II trial tests how well radiation therapy with pembrolizumab and chemotherapy (paclitaxel or nab-paclitaxel or carboplatin and gemcitabine) works in treating patients with PD-L1 positive triple negative breast cancer…
- Trial name
- NCT06492759
- Testing
- Radiation Therapy, Pembrolizumab, Nab-paclitaxel
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Emory University
Brain Injuries
Effect of Bevacizumab on Asymptomatic Radiotherapy-induced Brain Injury
To investigate the effect of Bevacizumab on asymptomatic radiotherapy-induced brain injury patients with head and neck cancer.
- Trial name
- BRAIN (NCT05303259)
- Testing
- Bevacizumab
- Where
- China
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
mCRPC (Metastatic Castration-resistant Prostate Cancer), Advanced Malignant Solid Tumor
A Study of MHB048C in Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multicenter Phase I/II study of MHB048C in patients with advanced solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of…
- Trial name
- NCT07192120
- Testing
- MHB048C for Injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Multiple Myeloma
IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
The purpose of this study is to provide continued access to ixazomib and/or lenalidomide to participants who are continuing to have clinical benefit and to continue collecting relevant safety data to monitor safety in…
- Trial name
- NCT01850524
- Testing
- Ixazomib, Dexamethasone, Lenalidomide
- Where
- 147 sites in United States, Belgium and 5 more
- Volunteers
- 705 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Multiple Myeloma
Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma
The non-interventional study SEATTLE aims to answer open scientific questions regarding QoL and tolerability/safety and AE management of selinexor as well as effectiveness and dosing in clinical routine.
- Trial name
- SEATTLE (NCT05954780)
- Testing
- Selinexor
- Where
- 2 sites in Austria, Germany
- Volunteers
- 75 people
- Sponsor
- iOMEDICO AG
Recurrent Bladder Carcinoma, Bladder Cancer Stage 0
sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer
This phase I trial studies the side effects and best dose of recombinant EphB4-HSA fusion protein (sEphB4-HSA), and to see how well it works in treating participants with bladder cancer that has come back or that isn't responding…
- Conditions
- Recurrent Bladder Carcinoma, Bladder Cancer Stage 0, Bladder Cancer Stage I
- Trial name
- NCT03552796
- Testing
- Pharmacokinetic Study, Recombinant EphB4-HSA Fusion Protein
- Where
- United States
- Sponsor
- University of Southern California
Gastric Cancer
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
This randomized, open-label, multicenter, international Phase IIIb study will compare the efficacy and safety of two Herceptin dosing regimens in combination with cisplatin/capecitabine chemotherapy in participants with…
- Trial name
- HELOISE (NCT01450696)
- Testing
- Capecitabine, Cisplatin, Herceptin
- Where
- 117 sites in United States, Australia and 23 more
- Volunteers
- 296 people
- Sponsor
- Hoffmann-La Roche
Brain and Central Nervous System Tumors
Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.
- Trial name
- NCT00006358
- Testing
- temozolomide, thalidomide
- Where
- 11 sites in United States
- Volunteers
- 44 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Unspecified Adult Solid Tumor, Protocol Specific
Vaccine Therapy With or Without Sargramostim in Treating Patients With Cancer
Phase I trial to compare the effectiveness of vaccine therapy with or without sargramostim in treating patients who have solid tumors. Vaccines may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00009958
- Testing
- recombinant fowlpox-CEA(6D)/TRICOM vaccine, recombinant vaccinia-CEA(6D)-TRICOM vaccine, sargramostim
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Major Depressive Disorder, Neoplasms
Pilot Study to Evaluate Individualized Choice of Antidepressants in Patients With Cancer
This is a pilot study to test the hypothesis that the antidepressants mirtazapine and citalopram are effective treatment for major depressive disorder (MDD) in cancer patients.
- Trial name
- NRR (NCT01725048)
- Testing
- Mirtazapine, Citalopram
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non Hodgkin Lymphoma, Follicular Lymphoma
Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma
This is a prospective multicenter phase II pilot trial designed with the purpose of dose finding to evaluate the efficacy and safety of treatment with Lenalidomide plus R-CHOP21 (LR-CHOP21) for elderly patients with untreated…
- Trial name
- REAL07 (NCT00907348)
- Testing
- LR-CHOP21
- Where
- 18 sites in Italy
- Volunteers
- 49 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Pancreatic Cancer
Molecularly Tailored Therapy for Pancreas Cancer
Patient therapy is tailored according to the molecular profile of the patient's tumor.
- Trial name
- NCT01888978
- Testing
- Gem-OX, Gem-5FU, Gem-Tax
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Georgetown University
Squamous Cell Carcinoma of the Oral Cavity and Oropharynx, Oral Mucositis
DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer
To assess the efficacy of SGX942 compared to placebo in decreasing the duration of severe oral mucositis in patients receiving chemoradiation treatment for the treatment of head and neck cancer
- Trial name
- NCT03237325
- Testing
- SGX942
- Where
- 53 sites in United States, Belgium and 3 more
- Volunteers
- 266 people
- Sponsor
- Soligenix
Advanced Lung Non-Small Cell Carcinoma, Non-Small Cell Carcinoma of Lung, TNM Stage 4
A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy
Metastatic lung cancer is the leading cause of cancer mortality worldwide with a 5-year survival of less than 5%. With the approval of programmed cell death 1 (PD-1) inhibitors in advanced lung cancer, such as pembrolizumab…
- Trial name
- NCT04856176
- Testing
- Granulocyte-Macrophage Colony-Stimulating Factor, Pembrolizumab, pemetrexed
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Tufts Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.